Effects of Low-Dose ‘Factor VIII Inhibitor Bypassing Activity (FEIBA)’ in Resistant Haemophilia | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Effects of Low-Dose ‘Factor VIII Inhibitor Bypassing Activity (FEIBA)’ in Resistant Haemophilia

Acta Haematol (1980) 64 (1): 12–17.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data

Matteo Rota
Paolo A. Cortesi
Roberto Crea
Alessandro Gringeri
Lorenzo G. Mantovani

Blood Advances (2017) 1 (26): 2637.

Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression

M. J. TREUR
F. MCCRACKEN
B. HEEG
A. V. JOSHI
M. F. BOTTEMAN
F. DE CHARRO
B. VAN HOUT

Haemophilia (2009) 15 (2): 420.

The Role of Prothrombin Complex Concentrates In the Treatment of Hemophiliacs with Factor VIII Inhibitors

J. M. Lusher

Scandinavian Journal of Haematology (2009) 33 (S40): 195.